Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.

Infectious Diseases: Pathophysiology, Diagnostics and Prevention. Int J Mol Sci (2016) 0.75

ORF3 as a sensitive and specific diagnostic index for hepatitis E. Exp Ther Med (2017) 0.75

Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88

Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 3.84

Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS (2008) 2.83

Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27

Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol (2013) 2.09

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis (2003) 1.93

Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol (2007) 1.90

Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 1.77

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol (2004) 1.49

Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med (2007) 1.22

Molecular serum markers of liver fibrosis. Biomark Insights (2012) 1.20

Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis (2013) 1.14

Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta (2012) 1.07

The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol (2015) 1.06

Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol (2015) 1.03

Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) (2003) 1.03

Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology (2002) 0.97

Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain (2003) 0.96

Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol (2009) 0.94

Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2007) 0.93

Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem (2000) 0.89

Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion (2005) 0.89

Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS (2007) 0.88

Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials (2002) 0.86

Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients. Clin Biochem (2012) 0.80

Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features. Panminerva Med (2009) 0.80

Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects. Medicine (Baltimore) (2016) 0.77